Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction

Table 1 Plasma Cytokine and Chemokine C_max/T_max

Median C_max pg/ml [T_max h]
Analyte	TransCon Vehicle	20 µg IT TransCon TLR7/8 Agonist	20 µg IT Soluble resiquimod	Fold difference (Soluble resiquimod C_max/ TransCon TLR7/8 Agonist C_max)
IFN-γ	0.465 [LLOQ]	4.28 [6]	42.5 [6]	9.9
IL-12p70	4.25 [6]	13.61 [3]	43.23 [3]	3.18
IL-15/IL-15R	4.38 [LLOQ]	26.96 [6]	65.82 [3]	2.44
TNF-α	4.64 [3]	29.83 [3]	779.94 [1]	26.15
IP-10	94.89 [24]	463.54 [10]	2904.66 [3]	6.27
MCP-1	43.61 [24]	552.49 [10]	4105.73 [3]	7.43
MIP-1α	1.31 [3]	6.13 [3]	95.02 [1]	15.5
MIP-1β	3.4 [6]	35.21 [3]	933.93 [1]	26.52

Median maximum concentration (C_max), the time at which the median maximum concentration was measured [T_max in hours (h), in parentheses], and fold difference in median C_max between TransCon TLR7/8 Agonist and soluble resiquimod treatment for plasma analytes measured from animals described in Fig. 2B are shown

ISSN: 1475-2867